TD Cowen Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by TD Cowen from $1,020.00 to $1,030.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective indicates a potential upside of 13.24% from the company’s current price.

Several other research analysts have also recently weighed in on REGN. Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Finally, UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Up 0.2 %

REGN stock traded up $2.26 during trading on Wednesday, hitting $909.58. 162,977 shares of the stock traded hands, compared to its average volume of 486,978. The stock has a market cap of $99.84 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33. The firm’s 50 day moving average is $951.41 and its two-hundred day moving average is $893.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the prior year, the company posted $10.96 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 38.8 EPS for the current year.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Insiders have sold 11,022 shares of company stock worth $10,552,991 over the last ninety days. Corporate insiders own 8.83% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 9.7% in the third quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 39 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 67.1% in the 3rd quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 100 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% in the 3rd quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 15 shares during the last quarter. Private Trust Co. NA grew its position in Regeneron Pharmaceuticals by 30.4% in the third quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 94 shares in the last quarter. Finally, CX Institutional increased its stake in Regeneron Pharmaceuticals by 10.7% during the third quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.